Total: 1
Randomized controlled trials (RCTs) are fundamental tools for causal inference across technology companies, pharmaceutical research, and federal agencies. While the standard difference-in-means estimator provides unbiased treatment effect estimates, it often lacks precision, particularly when treatment effects are heterogeneous or outcomes exhibit heavy-tailed distributions. Although numerous precision-enhancing methods exist---from covariate adjustment techniques to variance reduction strategies---recent research demonstrates that no single estimator performs optimally across all datasets. Rather than seeking the best estimator for individual RCTs, which risks compromising scientific validity through convenient selection, we propose a principled framework for identifying optimal estimators within families of RCTs based on specific analytical goals. Our approach uses sample splitting to estimate the distribution of evaluation metrics (e.g., mean squared error, regret) across RCT families, enabling systematic comparisons between estimators while maintaining asymptotic guarantees. We demonstrate this framework using a sample of Amazon's Supply Chain Optimization Technology trials and the Strengthening Democracy Challenge dataset (25 interventions). Results reveal that optimal estimators vary significantly by analytical objective: weighted least squares performs best for inference goals, while difference-in-means minimizes regret for decision-making contexts. This work provides actionable guidance for estimator selection while preserving methodological rigor across diverse research applications.